ALTSTATION.IO

Danaher Corporation (DHR) Stock Analysis

By Nova Skye | AltStation.io | Updated September 11, 2026

Price

$201.11

Change

-1.83%

Market Cap

$141.38B

Avg Volume

4.6M

Company Overview

Headquartered in Washington, D.C., Danaher Corporation operates in the healthcare sector, focusing strictly on diagnostics and research. The company makes money across three core segments: Diagnostics, Life Sciences, and Biotechnology. It sells lab hardware, mass spectrometers, clinical analyzers, and manufacturing consumables to hospitals, pharmaceutical developers, and academic research labs. Customers rely on these tools to develop therapeutics, run genomic sequencing, and diagnose patient illnesses in critical care settings.

Danaher is a dominant market leader rather than a speculative challenger. Its primary edge is a razor-and-blade business model, where consumables, software, and services drove 81.11% of total revenue in 2024. Once a hospital or lab installs Danaher equipment from brands like Beckman Coulter, Pall, or Sciex, they are locked into buying high-margin proprietary consumables for years. The main threat is direct, aggressive pricing and scale competition from Thermo Fisher Scientific and Agilent Technologies in bidding for biopharma manufacturing contracts.

Right now, Danaher is streamlined as a pure-play life sciences and diagnostics operator after completing the spin-off of its environmental division, Veralto, on September 30, 2023. The company doubled down on specialized research tools by completing its $5.7 billion acquisition of Abcam on December 6, 2023. In 2024, Danaher generated $23.9 billion in revenue, with Diagnostics accounting for 41%, Life Sciences contributing 31%, and Biotechnology generating 28%. The business is positioned cleanly in essential healthcare workflows, though sustained top-line momentum depends on biopharma customer spending rebounding from recent post-pandemic budget cuts.

Key Financials

Market Cap

$141.38B

Revenue

$25.11B

EBITDA

$8.03B

Gross Margin

58.8%

Profit Margin

15.9%

Revenue Growth

5.5%

Total Cash

$4.35B

Total Debt

$27.86B

Free Cash Flow

$4.33B

52-Week Price Performance Analysis

Price Statistics

P/E Ratio

35.85

Forward P/E

21.63

Beta

0.81

52-Week High

$242.80

52-Week Low

$160.93

EPS

$5.61

50-Day Avg

$202.05

200-Day Avg

$202.64

Price/Book

2.69

Technical Analysis

DHR trades at $201.11, 49% of the way from its exact 52-week low of $160.60 to its exact 52-week high of $241.78. The stock is 17.06% below that high but remains 24.87% above the low. Price is 4.34% below the 20-day moving average of $209.64, which puts the short-term trend firmly on the weak side. Momentum is negative, with declines of 4.47% over the last five trading days and 2.56% over the last 20 trading days. Near-term support is $194.78, while $218.85 is the resistance level buyers need to reclaim.

Recent News and Developments

UBS starts Danaher at Buy with $250 target

UBS initiated coverage of Danaher on September 9 with a Buy rating and a $250 price target, implying 21.81% upside from the price cited by MarketBeat. Analyst Douglas Schenkel expects Danaher to return to low-single-digit organic growth in 2026 and mid-single-digit growth in 2027. Source: MarketBeat

DHR slides across three consecutive sessions

Danaher closed at $207.66 on September 4, $205.23 on September 8, and $204.85 on September 9. That is a 1.35% decline from the September 4 close, showing that UBS’s bullish initiation did not immediately reverse the selling. Source: Stock Analysis

Cepheid details Ebola diagnostic response

Danaher subsidiary Cepheid published a September 9 update on its response to the 2026 Ebola Bundibugyo outbreak in Africa. The company said it is supporting the response with rapid molecular diagnostics and regional partnerships built around its GeneXpert and Xpert Ebola tests. Source: Cepheid

Market Sentiment and Analyst Recommendations

Bull Case

Danaher generated $25.11 billion in revenue, and revenue growth is positive at 5.5%. Wall Street is firmly bullish, with 23 analysts assigning the stock a strong_buy recommendation. Their average target is $229.09, compared with the current price of $201.11. UBS added another bullish call on September 9, starting coverage with a Buy rating and a $250 target. UBS analyst Douglas Schenkel expects Danaher to return to low-single-digit organic growth in 2026 and mid-single-digit growth in 2027. The bull case is straightforward: revenue is growing, analysts expect further improvement, and the stock remains 17.06% below its 52-week high.

Bear Case

DHR is not cheap at 35.85 times earnings, especially with revenue growing only 5.5%. The balance sheet also carries $27.86 billion in debt against $4.35 billion in cash. Price momentum is deteriorating, with the stock down 4.47% over five trading days and 2.56% over 20 trading days. The stock is also 4.34% below its 20-day moving average, confirming that sellers currently control the short-term trend. DHR closed at $207.66 on September 4, $205.23 on September 8, and $204.85 on September 9, a 1.35% decline from the September 4 close despite the UBS Buy initiation. The analyst target range of $195 to $310 shows major disagreement, and its low end sits below the current $201.11 price.

What to Watch

The first technical test is whether DHR can hold the 30-day low of $194.78. A break below that level would strengthen the bearish momentum signal, while a move above the $209.64 moving average would improve the setup. The larger confirmation level is $218.85, the 30-day high and stated near-term resistance. Investors should track whether revenue growth holds above the reported 5.5% rate and whether the business moves toward the organic-growth path UBS outlined on September 9. Debt of $27.86 billion and cash of $4.35 billion also deserve close attention because the current gap limits financial flexibility. Cepheid’s September 9 Ebola-response update is a concrete operating development to monitor, but the key question is whether diagnostic activity translates into stronger company-level growth.

Analyst Consensus

STRONG BUY

Based on 23 analyst opinions

Low Target

$195.00

Mean Target

$229.09

High Target

$310.00

Earnings and Financial Data

Sector

Healthcare

Industry

Diagnostics & Research

Employees

58,000

Earnings & Dividends

Next Earnings

Oct 20, 2026

EPS (Trailing)

$5.61

Dividend Yield

78.0%

Payout Ratio

25.7%

Frequently Asked Questions

Is DHR a good stock to buy?

DHR carries a strong_buy recommendation from 23 analysts, and the $229.09 average target is above the current $201.11 price. The takeaway is that analyst sentiment is bullish, but the 35.85 P/E demands continued growth.

What is DHR’s price target?

The average analyst target is $229.09, with estimates ranging from $195 to $310. The takeaway is that analysts see upside on average, but the wide range signals substantial uncertainty.

Is DHR stock overvalued?

DHR trades at a P/E ratio of 35.85 while reported revenue growth is 5.5%. The takeaway is that the valuation is demanding relative to the current growth rate.

What are DHR’s support and resistance levels?

Near-term support is $194.78, and near-term resistance is $218.85. The takeaway is that those are the key levels framing the current trading range.

How far is DHR from its 52-week high?

DHR is 17.06% below its exact 52-week high of $241.78 and 24.87% above its exact 52-week low of $160.60. The takeaway is that the stock sits near the middle of its annual range, at the 49% position.

Related Stock Reports

Disclaimer: This report is for informational purposes only and does not constitute financial advice. The analysis and opinions expressed are those of AltStation.io and should not be relied upon as the sole basis for investment decisions. Always conduct your own research and consult with a qualified financial advisor before making investment decisions. Past performance does not guarantee future results. Updated September 11, 2026.